Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GALR1 | P47211 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863152 | 0.91 | CA2 (0.54) | CYP4F2CYP4A11CA2NPC1RAB9A | |
| SCHEMBL5863075 | 0.91 | BCL2 (0.49) | CYP4F2CYP4A11CA2NPC1RAB9A | |
| SCHEMBL5863076 | 0.84 | MEN1 (0.52) | CYP4F2CYP4A11CA2NPC1ALDH1A1 | |
| SCHEMBL1996600 | 0.83 | CYP4F2 (0.61) | CYP4F2CYP4A11NPC1ALDH1A1MAPT | |
| SCHEMBL5863108 | 0.82 | CYP4F2 (0.46) | CYP4F2CYP4A11CA2NPC1ALDH1A1 | |
| SCHEMBL5863364 | 0.82 | TSHR (0.46) | CYP4F2CYP4A11CA2ALDH1A1MAPT | |
| SCHEMBL29617015 | 0.81 | TP53 (0.62) | CYP4F2CYP4A11CA2NPC1ALDH1A1 | |
| SCHEMBL15023832 | 0.81 | CA2 (0.65) | CYP4F2CYP4A11CA2NPC1ALDH1A1 | |
| SCHEMBL4193217 | 0.79 | TP53 (0.61) | CYP4F2CYP4A11CA2TP53POLB | |
| SCHEMBL1993886 | 0.79 | CYP4F2 (0.56) | CYP4F2CYP4A11NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | CYP4F2 3158/4885CYP4A11 1583/4885CA2 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.